Agilent grew revenue 8.1% to $1.88 billion in fiscal Q3 2026 and lifted full-year guidance, but a $20 million tariff refund supplied about a third of the margin expansion and a prior-year tax one-off masks 21% pre-tax profit growth.
Revenue up 8%, but the quarter was won on margin — and about a third of the margin gain was a tariff refund
Agilent Technologies makes the instruments, consumables, software and services that laboratories use to analyse substances — from a pharmaceutical company checking drug purity to a hospital lab staining tissue to look for cancer. For the third quarter of its fiscal 2026 (the three months ended July 31, 2026; Agilent's fiscal year ends October 31), revenue was $1,878 million, up 8.1% from $1,738 million a year earlier.
The revenue line is the less interesting half. GAAP operating margin — the share of revenue left after all operating costs but before interest and tax — went from 20.7% to 23.6%, and gross margin jumped 4.4 percentage points to 55.5%. Management raised full-year revenue, margin and earnings guidance on the back of it. But $20 million of that operating profit came from refunds of US import tariffs that a court ruled invalid, and Agilent's own Q4 guidance assumes none of it repeats.
Metric
Q3 FY2026
Q3 FY2025
YoY Change
Net revenue
$1,878M
$1,738M
+8.1% (+7.3% core)
Gross margin
55.5%
51.1%
+4.4 ppt
GAAP operating margin
23.6%
20.7%
+2.9 ppt
Non-GAAP operating margin
28.3%
25.1%
+3.2 ppt
Read 0 community reports on Agilent Technologies, or write your own.Write a report
Agilent reports "core" revenue growth alongside the headline figure. Core strips out two things that flatter or depress the reported number without reflecting underlying demand: currency movements (a weaker dollar makes foreign sales translate into more dollars) and businesses acquired or sold in the past twelve months. Core growth was 7.3%.
The reconciliation in the earnings release puts exact dollars on the gap: of the $140 million revenue increase, $4 million came from currency and $10 million from acquisitions, leaving roughly $126 million of genuine growth. So the quarter was overwhelmingly organic — unusual and worth stating plainly, because the acquisition (Biocare, below) closed mid-quarter and could easily have carried more of the load.
The $10 million of acquired revenue all sits in Life Sciences and Diagnostics Markets, whose core revenue was $736 million against $746 million reported. That trims the segment's growth from 11% to 10% — still the fastest of the three, but the headline overstates it slightly.
By end market, the 10-Q is specific about what worked and what didn't: growth was "strong in the pharmaceutical and the diagnostics and clinical markets partially offset by declines in revenue in the academia and government market," with chemical and advanced materials strong and food declining. Pharmaceutical demand appearing as the lead driver in all three segments is the signal here; academia and government weakening in two of them is the offset, consistent with public-sector research budgets under pressure.
Geographically the 10-Q discloses only three regions, and does not break out China:
Region
Q3 FY2026
Q3 FY2025
YoY Change
Americas
$761M
$683M
+11.4%
Asia Pacific
$613M
$563M
+8.9%
Europe
$504M
$492M
+2.4%
Europe is the weak spot, and weaker than it looks: total revenue carried about a 1 percentage point currency tailwind in the quarter, so Europe's 2.4% reported growth is close to flat in local-currency terms. Within Life Sciences and Diagnostics Markets, European revenue was $201 million in both years — exactly flat.
Where the margin came from
The clearest line in the income statement is cost of products: $559 million, down from $577 million, even though product revenue rose $103 million. Selling products for more while paying less to make them is what produced the 4.4-point gross margin gain.
The 10-Q lists the causes in order: "higher sales volume, a net benefit from tariff refunds, targeted price increases, favorable business mix, lower intangible amortization expense and lower restructuring expense partially offset by wage increases and higher variable pay."
Two of those six deserve separating out, because they are not repeatable operating improvements:
Tariff refunds. On February 20, 2026 the US Supreme Court invalidated certain tariffs imposed under the International Emergency Economic Powers Act, and the Court of International Trade ordered US Customs and Border Protection to refund them. Agilent recognised a $20 million net benefit in operating income this quarter — worth roughly 1.1 percentage points of margin, or about a third of the 3.2-point non-GAAP operating margin expansion. Agilent is explicit that further refunds are treated as a gain contingency, recognised only when actually realised, and that more claims are outstanding with uncertain timing. Strip the refund out and underlying non-GAAP margin expansion was closer to 2.1 points — still good, just not 3.2.
Lower intangible amortization and restructuring. Amortization of acquisition-related intangibles fell to $21 million from $26 million and restructuring charges to $15 million from $17 million. These are comparison effects rolling off, not operations improving.
Working against margin: operating expenses grew faster than revenue. R&D rose 10% to $123 million and selling, general and administrative expense rose 14% to $475 million, the latter "primarily due to higher costs from transformational initiatives, higher variable pay and wage increases." Higher variable pay is itself a consequence of the good quarter — Agilent is paying out bonuses because it is beating plan.
Why GAAP EPS grew 8% while non-GAAP EPS grew 18%
The 10-point gap between the two EPS growth rates has two separate causes, and neither is a warning sign on its own.
The first is tax, and it is entirely a prior-year distortion. Agilent's tax rate this quarter was 18.5%, with "no significant discrete items." A year ago it was 8.2%, because of "the tax benefit of $28 million related to the release of tax reserves due to a remeasurement of the liability" — a one-off. Pre-tax income grew 21% (to $444 million from $366 million); net income grew only 7.7% because last year's tax bill was artificially small. Judged on pre-tax profit, GAAP earnings growth was far better than the 8.5% EPS line suggests.
The second is the size of the non-GAAP adjustments, which grew: $88 million excluded this quarter against $77 million a year ago. The item driving that is transformational initiatives, which doubled to $37 million from $18 million — spending on manufacturing transfers, site consolidations, legal-entity reorganisations and system replacements under what management calls the Ignite Operating System. These are real cash costs excluded from non-GAAP profit, and they have now been recurring for multiple years. An investor relying on the $1.62 figure is being shown a company spending $37 million a quarter on a transformation that is treated as though it were outside normal operations. The savings it generates, by contrast, flow straight into the non-GAAP numbers.
Biocare: $950 million for pathology, funded with new debt
On June 24, 2026 Agilent closed the acquisition of Biocare for $950 million net, adding clinical and research pathology products to the Life Sciences and Diagnostics Markets segment. The purchase price landed as $549 million of goodwill and $520 million of other intangible assets — meaning almost the entire price was paid for intangible value rather than tangible assets, which is normal for a diagnostics business but does mean amortization will rise from here. Agilent guides to roughly $27 million per quarter of intangible amortization going forward, against $21 million this quarter.
Agilent chose not to present pro forma results because "the effects of the acquisition were not material to our condensed consolidated financial statements" — consistent with the $10 million of revenue contribution in the five weeks it was owned.
Funding came partly from $600 million of 4.90% senior notes issued June 25, 2026 and maturing January 2032. Long-term debt rose to $3,645 million from $3,050 million at the October 31, 2025 year end, while cash was essentially unchanged at $1,758 million versus $1,789 million. That is the notable part of the balance sheet: Agilent absorbed a $950 million acquisition, paid $216 million of dividends and repurchased $295 million of stock over the nine months, and still ended with roughly the cash it started with, on $1,064 million of operating cash flow (up from $1,014 million). Nothing here constrains further deals — $1,654 million of buyback authorisation also remains.
Guidance, and what it implies
Management raised the full year:
FY2026 guidance
Now
Change vs prior
Revenue
$7.49–7.51B (+7.8–8.1% reported, +5.8–6.0% core)
+65 bps at midpoint
Non-GAAP operating margin expansion
over 130 bps (incl. ~30 bps tariff refunds)
raised
Non-GAAP EPS
$6.18–6.21
+15 cents at midpoint
Fourth-quarter guidance is revenue of $1.98–2.00 billion (+6.4–7.4% reported, +5.2–6.2% core) and non-GAAP EPS of $1.71–1.74, and it "does not include any future benefit from tariff refunds."
Two things follow from those numbers that the press release does not spell out.
First, the raise is smaller than the beat. Non-GAAP EPS guidance went up 15 cents at the midpoint, but the quarter itself contained a 6-cent tariff benefit — so only about 9 cents is an upgrade to the underlying business, and the full-year margin guidance explicitly carries 30 basis points of that tariff refund through to the annual figure. A reader taking "raises guidance" at face value will overstate how much better Agilent now expects the business to be.
Second, guidance implies core growth slows. Q4 core growth of 5.2–6.2% sits below the 7.3% just delivered. Some of that is prudence, but the Q3 core figure also benefited from an easy prior-year comparison — fiscal 2025 was the tail of what management describes as "an extended period of constrained capital spending" by customers. The forward-looking statement that customer "capital budget availability has largely normalized" is the single most important claim in the filing for anyone modelling fiscal 2027: normalised means instruments are being bought again, but it also means the recovery comparison effect stops helping.
My read: the underlying trajectory is genuinely improving — 2.1 points of tariff-free non-GAAP margin expansion on 7.3% core growth, with pharmaceutical demand leading in all three segments, is a good quarter by any standard, and the recurring services-and-consumables business in Agilent CrossLab ($786 million, now the largest segment, at a 34.3% operating margin) gives the mix a stability that instrument makers usually lack. The three things to watch are Europe, which is not growing in local currency; the academia and government end market, which is shrinking; and whether transformational-initiative spending at $37 million a quarter starts to fall, because until it does the gap between GAAP and non-GAAP earnings stays wide by choice rather than by circumstance.
Takeaway: Agilent's headline story — 8% growth, margins up nearly 3 points, guidance raised — is roughly two-thirds earned and one-third borrowed. A $20 million tariff refund that Agilent itself excludes from Q4 guidance supplied about a third of the margin expansion, and last year's abnormally low 8.2% tax rate is what makes GAAP EPS growth look pedestrian at 8% when pre-tax profit actually grew 21%. The durable signal is 7.3% core growth led by pharmaceutical demand across all three segments against a customer base whose capital budgets have, in management's words, "largely normalized."
Source: Agilent Technologies, Inc. Form 10-Q for the fiscal quarter ended July 31, 2026 (filed September 1, 2026) and Exhibit 99.1 to the Form 8-K filed August 26, 2026.